Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity

Reggie C Hamdy1, Kathleen Montpetit, Ellen M Raney

  • 1Shriners Hospital for Children, Montreal, Quebec, Canada. rhamdy@shriners.mcgill.ca

Insights

Botulinum toxin type A (BtX-A) injections show promise in reducing pain and improving quality of life for children undergoing limb lengthening surgery. This pilot study found BtX-A safe and effective, warranting further investigation.

Area of Science:

  • Orthopedic surgery
  • Pediatric orthopedics
  • Pain management

Background:

  • Ilizarov technique is common for pediatric lower limb lengthening and deformity correction.
  • Postoperative pain significantly impacts children's quality of life and mobility.
  • Limited evidence exists for botulinum toxin type A (BtX-A) use in this context.

Purpose of the Study:

  • Assess feasibility of a randomized clinical trial for children undergoing limb correction.
  • Provide preliminary evidence on the efficacy of BtX-A for pain management in this population.

Main Methods:

  • A pilot randomized controlled trial involving 52 pediatric patients (mean age 13.7 years).
  • Patients received either BtX-A or a saline placebo during surgery.
  • Outcomes measured included pain, medication use, quality of life, and functional mobility.

Main Results:

  • BtX-A group showed trends toward lower pain and reduced parenteral pain medication use (first 4 days).
  • Improved quality of life and functional mobility scores were observed in the BtX-A group.
  • All adverse events were expected complications; no serious adverse events related to BtX-A were reported.

Conclusions:

  • The study successfully established the feasibility of a randomized controlled trial design.
  • BtX-A injections appear safe and effective for pain reduction and functional improvement in pediatric limb correction.
  • A larger study is ongoing to confirm these promising preliminary findings.
Abstract

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Local Anesthetics: Clinical Application as Spinal Anesthesia01:11

Local Anesthetics: Clinical Application as Spinal Anesthesia

Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...